Abstract：
This is the first study presenting the overall descriptive epidemiology of multiple myeloma (MM), including incidence, mortality rate, and prevalence, in South Korea between 2010 and 2018 based on nationwide medical insurance coverage and mortality statistics data. The incidence of MM between 2010 and 2018 was obtained from nationwide medical claims data, and mortality data were obtained from the Korea National Statistical Office. The age-standardized incidence rate (ASIR) and mortality rate (ASMR) and one- and five-year survival rates of patients with MM each year were estimated. There were 10,835 patients with MM aged ≥ 20 years in South Korea between 2010 and 2018. The ASIR was 2.42/100,000 in 2010 and increased to 2.71/100,000 in 2018, with an annual percent change (APC) of 1.86% (95% CI = 0.74-2.99%, P = 0.005). While this trend was significant in women, it was not statistically significant in men. The ASMR did not significantly change over time. Furthermore, the median survival time of patients with MM diagnosed between 2010 and 2018 was 3.36 years. Notably, the one-year survival rate of patients was increased from 65.3% in 2010 to 76.2% in 2017. Finally, the proportion of patients with MM who received novel therapeutic agents, such as proteasome inhibitors or immunomodulatory drugs, as first-line treatment increased from 37.7% in 2010 to 97.8% in 2018. The ASIR and prevalence of MM in South Korea increased between 2010 and 2018, especially in women and the survival rate of patients with MM has increased.
摘要：
这是第一项介绍多发性骨髓瘤（MM）总体描述性流行病学的研究，包括发病率，死亡率,和患病率，2010年至2018年，韩国基于全国医疗保险覆盖率和死亡率统计数据。2010年至2018年MM的发生率来自全国范围的医疗索赔数据，死亡率数据来自韩国国家统计局。评估了MM患者的年龄标准化发病率（ASIR）和死亡率（ASMR）以及每年的一年和五年生存率。2010年至2018年，韩国有10,835例年龄≥20岁的MM患者。2010年ASIR为2.42/10万，2018年增至2.71/10万，年百分比变化（APC）为1.86%（95%CI=0.74-2.99%，P=0.005)。虽然这种趋势在女性中很明显，在男性中没有统计学意义。ASMR随时间没有显著变化。此外，2010年至2018年诊断为MM的患者的中位生存时间为3.36年.值得注意的是,患者的一年生存率从2010年的65.3%提高至2017年的76.2%.最后,接受新型治疗药物的MM患者比例，如蛋白酶体抑制剂或免疫调节药物，一线治疗从2010年的37.7%增加到2018年的97.8%.韩国MM的ASIR和患病率在2010年至2018年期间有所增加，尤其是在女性中，MM患者的生存率有所提高。
